An update on guanylyl cyclase C in the diagnosis, chemoprevention, and treatment of colorectal cancer

References

• Aka AA, Rappaport JA, Pattison AM, et al. Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer. Expert Rev Clin Pharmacol. 2017;10:549–557.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Goding Sauer A, et al. Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020;70:145–164.
   PubMed Web of Science ®Google Scholar
• Kuhn M. Molecular physiology of membrane guanylyl cyclase receptors. Physiol Rev. 2016;96:751–804.
   PubMed Web of Science ®Google Scholar
• Basu N, Saha S, Khan I, et al. Intestinal cell proliferation and senescence are regulated by receptor guanylyl cyclase C and p21. J Biol Chem. 2014;289:581–593.
   PubMed Web of Science ®Google Scholar
• Li P, Lin JE, Chervoneva I, et al. Homeostatic control of the crypt-villus axis by the bacterial enterotoxin receptor guanylyl cyclase C restricts the proliferating compartment in intestine. Am J Pathol. 2007;171:1847–1858.
   PubMed Web of Science ®Google Scholar
• Han X, Mann E, Gilbert S, et al. Loss of guanylyl cyclase C (GCC) signaling leads to dysfunctional intestinal barrier. PLoS One. 2011;6:e16139.
   PubMed Web of Science ®Google Scholar
• Lin JE, Snook AE, Li P, et al. GUCY2C opposes systemic genotoxic tumorigenesis by regulating AKT-dependent intestinal barrier integrity. PLoS One. 2012;7:e31686.
   PubMed Web of Science ®Google Scholar
• Rappaport JA, Waldman SA. The guanylate cyclase C-cGMP signaling axis opposes intestinal epithelial injury and neoplasia. Front Oncol. 2018;8:299.
   PubMed Web of Science ®Google Scholar
• Li P, Wuthrick E, Rappaport JA, et al. GUCY2C signaling opposes the acute radiation-induced GI syndrome. Cancer Res. 2017;77:5095–5106.
   PubMed Web of Science ®Google Scholar
• Gibbons AV, Lin JE, Kim GW, et al. Intestinal GUCY2C prevents TGF-beta secretion coordinating desmoplasia and hyperproliferation in colorectal cancer. Cancer Res. 2013;73:6654–6666.
   PubMed Web of Science ®Google Scholar
• Lin JE, Li P, Snook AE, et al. The hormone receptor GUCY2C suppresses intestinal tumor formation by inhibiting AKT signaling. Gastroenterology. 2010;138:241–254.
   PubMed Web of Science ®Google Scholar
• Wilson C, Lin JE, Li P, et al. The paracrine hormone for the GUCY2C tumor suppressor, guanylin, is universally lost in colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2014;23:2328–2337.
   PubMed Web of Science ®Google Scholar
• Steinbrecher KA, Tuohy TM, Heppner Goss K, et al. Expression of guanylin is downregulated in mouse and human intestinal adenomas. Biochem Biophys Res Commun. 2000;273:225–230.
   PubMed Web of Science ®Google Scholar
• Steinbrecher KA, Wowk SA, Rudolph JA, et al. Targeted inactivation of the mouse guanylin gene results in altered dynamics of colonic epithelial proliferation. Am J Pathol. 2002;161:2169–2178.
   PubMed Web of Science ®Google Scholar
• Blomain ES, Rappaport JA, Pattison AM, et al. APC-beta-catenin-TCF signaling silences the intestinal guanylin-GUCY2C tumor suppressor axis. Cancer Biol Ther. 2020;21:441–451.
   PubMed Web of Science ®Google Scholar
• Pattison AM, Barton JR, Entezari AA, et al. Silencing the intestinal GUCY2C tumor suppressor axis requires APC loss of heterozygosity. Cancer Biol Ther. 2020;21(9):799–805.
   Web of Science ®Google Scholar
• Bashir B, Merlino DJ, Rappaport JA, et al. Silencing the GUCA2A-GUCY2C tumor suppressor axis in CIN, serrated, and MSI colorectal neoplasia. Hum Pathol. 2019;87:103–114.
   PubMed Web of Science ®Google Scholar
• Birbe R, Palazzo JP, Walters R, et al. Guanylyl cyclase C is a marker of intestinal metaplasia, dysplasia, and adenocarcinoma of the gastrointestinal tract. Hum Pathol. 2005;36:170–179.
   PubMed Web of Science ®Google Scholar
• Carrithers SL, Barber MT, Biswas S, et al. Guanylyl cyclase C is a selective marker for metastatic colorectal tumors in human extraintestinal tissues. Proc Natl Acad Sci USA. 1996;93:14827–14832.
   PubMed Web of Science ®Google Scholar
• Cagir B, Gelmann A, Park J, et al. Guanylyl cyclase C messenger RNA is a biomarker for recurrent stage II colorectal cancer. Ann Inter Med. 1999;131:805–812.
   PubMed Web of Science ®Google Scholar
• Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759–767.
   PubMed Web of Science ®Google Scholar
• Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Pathol. 2011;6:479–507.
   PubMed Web of Science ®Google Scholar
• Zhang L, Shay JW. Multiple roles of APC and its therapeutic implications in colorectal cancer. J Natl Cancer Inst. 2017;109(8).
   Google Scholar
• Kouzmenko AP, Takeyama K, Kawasaki Y, et al. Truncation mutations abolish chromatin-associated activities of adenomatous polyposis coli. Oncogene. 2008;27:4888–4899.
   PubMed Web of Science ®Google Scholar
• Brocardo MG, Borowiec JA, Henderson BR. Adenomatous polyposis coli protein regulates the cellular response to DNA replication stress. Int J Biochem Cell Biol. 2011;43:1354–1364.
   PubMed Web of Science ®Google Scholar
• Jaiswal AS, Narayan S. Assembly of the base excision repair complex on abasic DNA and role of adenomatous polyposis coli on its functional activity. Biochemistry. 2011;50:1901–1909.
   PubMed Web of Science ®Google Scholar
• Gerlach JP, Emmink BL, Nojima H, et al. Wnt signaling induces accumulation of phosphorylated beta-catenin in two distinct cytosolic complexes. Open Biol. 2014;4:140120.
   PubMed Web of Science ®Google Scholar
• Bogaert J, Prenen H. Molecular genetics of colorectal cancer. Ann Gastroenterol. 2014;27:9–14.
   PubMedGoogle Scholar
• Cancer Genome Atlas N. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487(7407):330–337.
   PubMed Web of Science ®Google Scholar
• Nguyen LH, Goel A, Chung DC. Pathways of colorectal carcinogenesis. Gastroenterology. 2020;158(2):291–302.
   PubMed Web of Science ®Google Scholar
• Grady WM, Carethers JM. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology. 2008;135(4):1079–1099.
   PubMed Web of Science ®Google Scholar
• Powell SM, Zilz N, Beazer-Barclay Y, et al. APC mutations occur early during colorectal tumorigenesis. Nature. 1992;359:235–237.
   PubMed Web of Science ®Google Scholar
• Umar A, Risinger JI, Hawk ET, et al. Testing guidelines for hereditary non-polyposis colorectal cancer. Nat Rev Cancer. 2004;4:153–158.
   PubMed Web of Science ®Google Scholar
• Kambara T, Simms LA, Whitehall VL, et al. BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. Gut. 2004;53:1137–1144.
   PubMed Web of Science ®Google Scholar
• Piawah S, Venook AP. Targeted therapy for colorectal cancer metastases: a review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer. Cancer. 2019;125(23):4139–4147.
   PubMed Web of Science ®Google Scholar
• Katona BW, Weiss JM. Chemoprevention of colorectal cancer. Gastroenterology. 2020;158(2):368–388.
   PubMed Web of Science ®Google Scholar
• Thirion P, Michiels S, Pignon JP, et al. Meta-analysis group in C. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol. 2004;22:3766–3775.
   PubMed Web of Science ®Google Scholar
• Schulz S, Green CK, Yuen PS, et al. Guanylyl cyclase is a heat-stable enterotoxin receptor. Cell. 1990;63:941–948.
   PubMed Web of Science ®Google Scholar
• Thompson WJ, Piazza GA, Li H, et al. Exisulind induction of apoptosis involves guanosine 3ʹ,5ʹ-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res. 2000;60:3338–3342.
   PubMed Web of Science ®Google Scholar
• Garin-Laflam MP, Steinbrecher KA, Rudolph JA, et al. Activation of guanylate cyclase C signaling pathway protects intestinal epithelial cells from acute radiation-induced apoptosis. Am J Physiol Gastrointest Liver Physiol. 2009;296:G740–9.
   PubMed Web of Science ®Google Scholar
• Li P, Schulz S, Bombonati A, et al. Guanylyl cyclase C suppresses intestinal tumorigenesis by restricting proliferation and maintaining genomic integrity. Gastroenterology. 2007;133:599–607.
   PubMed Web of Science ®Google Scholar
• Mann EA, Harmel-Laws E, Cohen MB, et al. Guanylate cyclase C limits systemic dissemination of a murine enteric pathogen. BMC Gastroenterol. 2013;13:135.
   PubMed Web of Science ®Google Scholar
• Brenna O, Bruland T, Furnes MW, et al. The guanylate cyclase-C signaling pathway is down-regulated in inflammatory bowel disease. Scand J Gastroenterol. 2015;50:1241–1252.
   PubMed Web of Science ®Google Scholar
• Valentino MA, Lin JE, Snook AE, et al. A uroguanylin-GUCY2C endocrine axis regulates feeding in mice. J Clin Invest. 2011;121:3578–3588.
   PubMed Web of Science ®Google Scholar
• Kim GW, Lin JE, Snook AE, et al. Calorie-induced ER stress suppresses uroguanylin satiety signaling in diet-induced obesity. Nutr Diabetes. 2016;6:e211.
   PubMed Web of Science ®Google Scholar
• Lucas KA, Pitari GM, Kazerounian S, et al. Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev. 2000;52:375–414.
   PubMed Web of Science ®Google Scholar
• Currie MG, Fok KF, Kato J, et al. Guanylin: an endogenous activator of intestinal guanylate cyclase. Proc Natl Acad Sci USA. 1992;89:947–951.
   PubMed Web of Science ®Google Scholar
• Hamra FK, Forte LR, Eber SL, et al. Uroguanylin: structure and activity of a second endogenous peptide that stimulates intestinal guanylate cyclase. Proc Natl Acad Sci USA. 1993;90:10464–10468.
   PubMed Web of Science ®Google Scholar
• Ahsan MK, Tchernychev B, Kessler MM, et al. Linaclotide activates guanylate cyclase-C/cGMP/protein kinase-II-dependent trafficking of CFTR in the intestine. Physiological Reports. 2017;5(11).
   Web of Science ®Google Scholar
• Pattison AM, Blomain ES, Merlino DJ, et al. Intestinal enteroids model guanylate cyclase C-dependent secretion induced by heat-stable enterotoxins. Infect Immun. 2016;84:3083–3091.
   PubMed Web of Science ®Google Scholar
• Bijvelds MJ, Loos M, Bronsveld I, et al. Inhibition of heat-stable toxin-induced intestinal salt and water secretion by a novel class of guanylyl cyclase C inhibitors. J Infect Dis. 2015;212:1806–1815.
   PubMed Web of Science ®Google Scholar
• Waldman SA, Camilleri M. Guanylate cyclase-C as a therapeutic target in gastrointestinal disorders. Gut. 2018. DOI:10.1136/gutjnl-2018-316029
   PubMed Web of Science ®Google Scholar
• von Volkmann HL, Bronstad I, Gilja OH. Prolonged intestinal transit and diarrhea in patients with an activating GUCY2C mutation. PLoS One. 2017;12:e0185496.
   PubMed Web of Science ®Google Scholar
• von Volkmann HL, Nylund K, Tronstad RR, et al. An activating gucy2c mutation causes impaired contractility and fluid stagnation in the small bowel. Scand J Gastroenterol. 2016;51:1308–1315.
   PubMed Web of Science ®Google Scholar
• Fiskerstrand T, Arshad N, Haukanes BI, et al. Familial diarrhea syndrome caused by an activating GUCY2C mutation. N Engl J Med. 2012;366:1586–1595.
   PubMed Web of Science ®Google Scholar
• Romi H, Cohen I, Landau D, et al. Meconium ileus caused by mutations in GUCY2C, encoding the CFTR-activating guanylate cyclase 2C. Am J Hum Genet. 2012;90:893–899.
   PubMed Web of Science ®Google Scholar
• Smith A, Bulman DE, Goldsmith C, et al. Meconium ileus in a Lebanese family secondary to mutations in the GUCY2C gene. Eur J Hum Genet. 2015;23:990–992.
   PubMed Web of Science ®Google Scholar
• Wang R, Kwon IK, Thangaraju M, et al. Type 2 cGMP-dependent protein kinase regulates proliferation and differentiation in the colonic mucosa. Am J Physiol Gastrointest Liver Physiol. 2012;303:G209–19.
   PubMed Web of Science ®Google Scholar
• Kraft CL, Rappaport JA, Snook AE, et al. GUCY2C maintains intestinal LGR5(+) stem cells by opposing ER stress. Oncotarget. 2017;8:102923–102933.
   PubMedGoogle Scholar
• Pitari GM, Di Guglielmo MD, Park J, et al. Guanylyl cyclase C agonists regulate progression through the cell cycle of human colon carcinoma cells. Proc Natl Acad Sci USA. 2001;98:7846–7851.
   PubMed Web of Science ®Google Scholar
• Lin S, Wang J, Wang L, et al. Phosphodiesterase-5 inhibition suppresses colonic inflammation-induced tumorigenesis via blocking the recruitment of MDSC. Am J Cancer Res. 2017;7:41–52.
   PubMed Web of Science ®Google Scholar
• Lee K, AP G. The interaction between the Wnt/beta-catenin signaling cascade and PKG activation in cancer. J Biomed Res. 2017;31:189–196.
   PubMed Web of Science ®Google Scholar
• Li N, Lee K, Xi Y, et al. Phosphodiesterase 10A: a novel target for selective inhibition of colon tumor cell growth and beta-catenin-dependent TCF transcriptional activity. Oncogene. 2015;34:1499–1509.
   PubMed Web of Science ®Google Scholar
• Whitt JD, Li N, Tinsley HN, et al. A novel sulindac derivative that potently suppresses colon tumor cell growth by inhibiting cGMP phosphodiesterase and beta-catenin transcriptional activity. Cancer Prev Res (Phila). 2012;5:822–833.
   PubMed Web of Science ®Google Scholar
• Shailubhai K, Yu HH, Karunanandaa K, et al. Uroguanylin treatment suppresses polyp formation in the Apc(Min/+) mouse and induces apoptosis in human colon adenocarcinoma cells via cyclic GMP. Cancer Res. 2000;60:5151–5157.
   PubMed Web of Science ®Google Scholar
• Danaee H, Kalebic T, Wyant T, et al. Consistent expression of guanylyl cyclase-C in primary and metastatic gastrointestinal cancers. PLoS One. 2017;12:e0189953.
   PubMed Web of Science ®Google Scholar
• The cancer genome atlas. Acessed 2020 Jul 20. Available from: https://portal.gdc.cancer.gov/.
   Google Scholar
• Park J, Schulz S, Waldman SA. Intestine-specific activity of the human guanylyl cyclase C promoter is regulated by Cdx2. Gastroenterology. 2000;119:89–96.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhou W, Velculescu VE, et al. Gene expression profiles in normal and cancer cells. Science. 1997;276:1268–1272.
   PubMed Web of Science ®Google Scholar
• Cohen MB, Hawkins JA, Witte DP. Guanylin mRNA expression in human intestine and colorectal adenocarcinoma. Lab Invest. 1998;78:101–108.
   PubMed Web of Science ®Google Scholar
• Lin JE, Colon-Gonzalez F, Blomain E, et al. Obesity-induced colorectal cancer is driven by caloric silencing of the guanylin-GUCY2C paracrine signaling axis. Cancer Res. 2016;76:339–346.
   PubMed Web of Science ®Google Scholar
• Li P, Lin JE, Snook AE, et al. ST-producing E. coli oppose carcinogen-induced colorectal tumorigenesis in mice. Toxins (Basel). 2017;9(9).
   Web of Science ®Google Scholar
• Lubbe WJ, Zuzga DS, Zhou Z, et al. Guanylyl cyclase C prevents colon cancer metastasis by regulating tumor epithelial cell matrix metalloproteinase-9. Cancer Res. 2009;69:3529–3536.
   PubMed Web of Science ®Google Scholar
• Zuzga DS, Pelta-Heller J, Li P, et al. Phosphorylation of vasodilator-stimulated phosphoprotein Ser239 suppresses filopodia and invadopodia in colon cancer. Int J Cancer. 2012;130:2539–2548.
   PubMed Web of Science ®Google Scholar
• Schoenfeld P, Lacy BE, Chey WD, et al. Low-dose linaclotide (72 mug) for chronic idiopathic constipation: a 12-week, randomized, double-blind, placebo-controlled trial. Am J Gastroenterol. 2018;113:105–114.
   PubMed Web of Science ®Google Scholar
• Brenner DM, Fogel R, Dorn SD, et al. Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials. Am J Gastroenterol. 2018. DOI:10.1038/s41395-018-0026-7
   Web of Science ®Google Scholar
• Sharman SK, Islam BN, Hou Y, et al. Cyclic-GMP-elevating agents suppress polyposis in Apc(Min) mice by targeting the preneoplastic epithelium. Cancer Prev Res (Phila). 2018;11:81–92.
   PubMed Web of Science ®Google Scholar
• Chang WL, Masih S, Thadi A, et al. Plecanatide-mediated activation of guanylate cyclase-C suppresses inflammation-induced colorectal carcinogenesis in Apc+/Min-FCCC mice. World J Gastrointest Pharmacol Ther. 2017;8:47–59.
   PubMedGoogle Scholar
• Weinberg DS, Lin JE, Foster NR, et al. Bioactivity of oral linaclotide in human colorectum for cancer chemoprevention. Cancer Prev Res (Phila). 2017;10:345–354.
   PubMed Web of Science ®Google Scholar
• Shah ED, Kim HM, Schoenfeld P. Efficacy and tolerability of guanylate cyclase-C agonists for irritable bowel syndrome with constipation and chronic idiopathic constipation: a systematic review and meta-analysis. Am J Gastroenterol. 2018;113:329–338.
   PubMed Web of Science ®Google Scholar
• Browning DD. The enduring promise of phosphodiesterase 5 inhibitors for colon cancer prevention. Translat Gastroenterol Hepatol. 2019;4:83.
   Web of Science ®Google Scholar
• Stoner GD, Budd GT, Ganapathi R, et al. Sulindac sulfone induced regression of rectal polyps in patients with familial adenomatous polyposis. Adv Exp Med Biol. 1999;470:45–53.
   PubMed Web of Science ®Google Scholar
• van Stolk R, Stoner G, Hayton WL, et al. Phase I trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis. Clin Cancer Res. 2000;6:78–89.
   PubMed Web of Science ®Google Scholar
• Arber N, Kuwada S, Leshno M, et al. Sporadic adenomatous polyp regression with exisulind is effective but toxic: a randomised, double blind, placebo controlled, dose-response study. Gut. 2006;55:367–373.
   PubMed Web of Science ®Google Scholar
• Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med. 1993;328:1313–1316.
   PubMed Web of Science ®Google Scholar
• Cruz-Correa M, Hylind LM, Romans KE, et al. Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study. Gastroenterology. 2002;122:641–645.
   PubMed Web of Science ®Google Scholar
• Li N, Xi Y, Tinsley HN, et al. Sulindac selectively inhibits colon tumor cell growth by activating the cGMP/PKG pathway to suppress Wnt/ -catenin signaling. Mol Cancer Ther. 2013;12(9):1848–1859.
   PubMed Web of Science ®Google Scholar
• Tinsley HN, Grizzle WE, Abadi A, et al. New NSAID targets and derivatives for colorectal cancer chemoprevention. Recent Results Cancer Res. 2013;191:105–120.
   PubMedGoogle Scholar
• Islam BN, Sharman SK, Hou Y, et al. Sildenafil suppresses inflammation-driven colorectal cancer in mice. Cancer Prev Res (Phila). 2017;10:377–388.
   PubMed Web of Science ®Google Scholar
• Huang W, Sundquist J, Sundquist K, et al. Use of phosphodiesterase 5 inhibitors is associated with lower risk of colorectal cancer in men with benign colorectal neoplasms. Gastroenterology. 2019;157:672–81 e4.
   PubMed Web of Science ®Google Scholar
• Muller C, Yurgelun M, Kupfer SS. Precision treatment and prevention of colorectal cancer-hope or hype? Gastroenterology. 2020;158:441–446.
   PubMed Web of Science ®Google Scholar
• Snook AE, Stafford BJ, Li P, et al. Guanylyl cyclase C-induced immunotherapeutic responses opposing tumor metastases without autoimmunity. J Natl Cancer Inst. 2008;100:950–961.
   PubMedGoogle Scholar
• Snook AE, Li P, Stafford BJ, et al. Lineage-specific T-cell responses to cancer mucosa antigen oppose systemic metastases without mucosal inflammatory disease. Cancer Res. 2009;69:3537–3544.
   PubMed Web of Science ®Google Scholar
• Snook AE, Magee MS, Schulz S, et al. Selective antigen-specific CD4(+) T-cell, but not CD8(+) T- or B-cell, tolerance corrupts cancer immunotherapy. Eur J Immunol. 2014;44:1956–1966.
   PubMed Web of Science ®Google Scholar
• Pernot S, Terme M, Voron T, et al. Colorectal cancer and immunity: what we know and perspectives. World J Gastroenterol. 2014;20:3738–3750.
   PubMed Web of Science ®Google Scholar
• Snook AE, Waldman SA. Advances in cancer immunotherapy. Discov Med. 2013;15:120–125.
   PubMed Web of Science ®Google Scholar
• Xiang B, Baybutt TR, Berman-Booty L, et al. Prime-boost immunization eliminates metastatic colorectal cancer by producing high-avidity effector CD8(+) T cells. J Immunol. 2017;198:3507–3514.
   PubMed Web of Science ®Google Scholar
• Snook AE, Baybutt TR, Hyslop T, et al. Preclinical evaluation of a replication-deficient recombinant adenovirus serotype 5 vaccine expressing guanylate cyclase C and the PADRE T-helper epitope. Human Gene Therapy Meth. 2016;27:238–250.
   PubMed Web of Science ®Google Scholar
• Snook AE, Baybutt TR, Xiang B, et al. Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients. J Immunother Cancer. 2019;7:104.
   PubMed Web of Science ®Google Scholar
• Flickinger JC Jr., Singh J, Carlson R, et al. Chimeric Ad5.F35 vector evades anti-adenovirus serotype 5 neutralization opposing GUCY2C-targeted antitumor immunity. J Immunother Cancer. J Immunother Cancer. 2020 Aug;8(2).
   Web of Science ®Google Scholar
• Baybutt TR, Flickinger JC Jr., Caparosa EM, et al. Advances in chimeric antigen receptor T-cell therapies for solid tumors. Clin Pharmacol Ther. 2019;105:71–78.
   PubMed Web of Science ®Google Scholar
• Gross G, Gorochov G, Waks T, et al. Generation of effector T cells expressing chimeric T cell receptor with antibody type-specificity. Transplant Proc. 1989;21:127–130.
   PubMed Web of Science ®Google Scholar
• Magee MS, Kraft CL, Abraham TS, et al. GUCY2C-directed CAR-T cells oppose colorectal cancer metastases without autoimmunity. OncoImmunology. 2016;5:e1227897.
   PubMed Web of Science ®Google Scholar
• Magee MS, Abraham TS, Baybutt TR, et al. Human GUCY2C-targeted Chimeric Antigen Receptor (CAR)-expressing T cells eliminate colorectal cancer metastases. Cancer Immunol Res. 2018;6:509–516.
   PubMed Web of Science ®Google Scholar
• Papachristos A, Pippa N, Demetzos C, et al. Antibody-drug conjugates: a mini-review. The synopsis of two approved medicines. Drug Deliv. 2016;23:1662–1666.
   PubMed Web of Science ®Google Scholar
• Peters C, Brown S. Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Biosci Rep. 2015;35(4).
   Web of Science ®Google Scholar
• Leung D, Wurst JM, Liu T, et al. Antibody conjugates-recent advances and future innovations. Antibodies (Basel). 2020;9(1):2.
   Google Scholar
• Marszalowicz GP, Snook AE, Magee MS, et al. GUCY2C lysosomotropic endocytosis delivers immunotoxin therapy to metastatic colorectal cancer. Oncotarget. 2014;5:9460–9471.
   PubMed Web of Science ®Google Scholar
• Almhanna K, Kalebic T, Cruz C, et al. Phase I study of the investigational anti-guanylyl cyclase antibody-drug conjugate TAK-264 (MLN0264) in adult patients with advanced gastrointestinal malignancies. Clin Cancer Res. 2016;22:5049–5057.
   PubMed Web of Science ®Google Scholar
• Almhanna K, Miron ML, Wright D, et al. Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C. Invest New Drugs. 2017;35:235–241.
   PubMed Web of Science ®Google Scholar
• Almhanna K, Wright D, Mercade TM, et al. A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C. Invest New Drugs. 2017;35:634–641.
   PubMed Web of Science ®Google Scholar
• Rahbari NN, Bork U, Motschall E, et al. Molecular detection of tumor cells in regional lymph nodes is associated with disease recurrence and poor survival in node-negative colorectal cancer: a systematic review and meta-analysis. J Clin Oncol. 2012;30:60–70.
   PubMed Web of Science ®Google Scholar
• Waldman SA, Hyslop T, Schulz S, et al. Association of GUCY2C expression in lymph nodes with time to recurrence and disease-free survival in pN0 colorectal cancer. JAMA. 2009;301:745–752.
   PubMed Web of Science ®Google Scholar
• Beaulieu M, Desaulniers M, Bertrand N, et al. Analytical performance of a qRT-PCR assay to detect guanylyl cyclase C in FFPE lymph nodes of patients with colon cancer. Diagn Mol Pathol. 2010;19:20–27.
   PubMedGoogle Scholar
• Sargent DJ, Resnick MB, Meyers MO, et al. Evaluation of guanylyl cyclase C lymph node status for colon cancer staging and prognosis. Ann Surg Oncol. 2011;18:3261–3270.
   PubMed Web of Science ®Google Scholar
• Haince JF, Houde M, Beaudry G, et al. Comparison of histopathology and RT-qPCR amplification of guanylyl cyclase C for detection of colon cancer metastases in lymph nodes. J Clin Pathol. 2010;63:530–537.
   PubMed Web of Science ®Google Scholar
• Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014;370:1287–1297.
   PubMed Web of Science ®Google Scholar
• Church TR, Wandell M, Lofton-Day C, et al. Present clinical study steering committee I, study T. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut. 2014;63:317–325.
   PubMed Web of Science ®Google Scholar
• Yamada T, Matsuda A, Koizumi M, et al. Liquid biopsy for the management of patients with colorectal cancer. Digestion. 2019;99:39–45.
   PubMed Web of Science ®Google Scholar
• Lan D, Niu J, Miao J, et al. Expression of guanylate cyclase-C, guanylin, and uroguanylin is downregulated proportionally to the ulcerative colitis disease activity index. Sci Rep. 2016;6:25034.
   PubMed Web of Science ®Google Scholar
• Di Guglielmo MD, Perdue L, Adeyemi A, et al. Immunohistochemical staining for uroguanylin, a satiety hormone, is decreased in intestinal tissue specimens from female adolescents with obesity. Pediatr Dev Pathol. 2017;21(3):285–295.
   PubMed Web of Science ®Google Scholar
• Merlino DJ, Barton JR, Charsar BA, et al. Two distinct GUCY2C circuits with PMV (hypothalamic) and SN/VTA (midbrain) origin. Brain Struct Funct. 2019;224:2983–2999.
   PubMed Web of Science ®Google Scholar
• Park J, Schulz S, Haaf J, et al. Ectopic expression of guanylyl cyclase C in adenocarcinomas of the esophagus and stomach. Cancer Epidemiol Biomarkers Prev. 2002;11:739–744.
   PubMed Web of Science ®Google Scholar